WELCOME TO OUR PARKINSON'S PLACE!

I HAVE PARKINSON'S DISEASES AND THOUGHT IT WOULD BE NICE TO HAVE A PLACE WHERE THE CONTENTS OF UPDATED NEWS IS FOUND IN ONE PLACE. THAT IS WHY I BEGAN THIS BLOG.

I COPY NEWS ARTICLES PERTAINING TO RESEARCH, NEWS AND INFORMATION FOR PARKINSON'S DISEASE, DEMENTIA, THE BRAIN, DEPRESSION AND PARKINSON'S WITH DYSTONIA. I ALSO POST ABOUT FUNDRAISING FOR PARKINSON'S DISEASE AND EVENTS. I TRY TO BE UP-TO-DATE AS POSSIBLE.

I AM NOT RESPONSIBLE FOR IT'S CONTENTS. I AM JUST A COPIER OF INFORMATION SEARCHED ON THE COMPUTER. PLEASE UNDERSTAND THE COPIES ARE JUST THAT, COPIES AND AT TIMES, I AM UNABLE TO ENLARGE THE WORDING OR KEEP IT UNIFORMED AS I WISH. IT IS IMPORTANT TO UNDERSTAND I AM A PERSON WITH PARKINSON'S DISEASE. I HAVE NO MEDICAL EDUCATION,

I JUST WANT TO SHARE WITH YOU WHAT I READ ON THE INTERNET. IT IS UP TO YOU TO DECIDE WHETHER TO READ IT AND TALK IT OVER WITH YOUR DOCTOR. I AM JUST THE COPIER OF DOCUMENTS FROM THE COMPUTER. I DO NOT HAVE PROOF OF FACT OR FICTION OF THE ARTICLE. I ALSO TRY TO PLACE A LINK AT THE BOTTOM OF EACH ARTICLE TO SHOW WHERE I RECEIVED THE INFORMATION SO THAT YOU MAY WANT TO VISIT THEIR SITE.

THIS IS FOR YOU TO READ AND TO ALWAYS KEEP AN OPEN MIND.

PLEASE DISCUSS THIS WITH YOUR DOCTOR, SHOULD YOU HAVE ANY QUESTIONS, OR CONCERNS. NEVER DO ANYTHING WITHOUT TALKING TO YOUR DOCTOR FIRST..

I DO NOT MAKE ANY MONEY FROM THIS WEBSITE. I VOLUNTEER MY TIME TO HELP ALL OF US TO BE INFORMED.

I WILL NOT ACCEPT ANY ADVERTISEMENT OR HEALING POWERS, HEALING FROM HERBS AND ETC. UNLESS IT HAS GONE THROUGH TRIALS AND APPROVED BY FDA. IT WILL GO INTO SPAM.

THIS IS A FREE SITE FOR ALL WITH NO ADVERTISEMENTS

THANK YOU FOR VISITING! TOGETHER WE CAN MAKE A DIFFERENCE!

TRANSLATE

Tuesday, October 25, 2016

Study Identifies Two New Genes Responsible for Alzheimer’s in African Americans

NEUROSCIENCE NEWS
Summary: Researchers have discovered two genetic risk factors for Alzheimer’s disease among African Americans.

Source: Boston University Medical Center.
In 2013, a genome-wide association study of AD in more than 5,500 African Americans identified two genetic risk factors for AD. NeuroscienceNews.com image is in the public domain.

Researchers have identified two new genetic risk factors for Alzheimer’s disease (AD) among African Americans.

The findings, which appear online in the journal Alzheimer’s and Dementia, may lead to the development of new therapies specifically targeting those genes.
Despite the fact that AD is more common in African Americans than Caucasians, the AD genetic risk profile for African Americans is more poorly understood. While more than 20 genes have been identified as risk factors for AD in Caucasians, fewer than five have been identified for African Americans.

In 2013, a genome-wide association study of AD in more than 5,500 African Americans identified two genetic risk factors for AD. This study looked at genetic variants across subjects’ entire genome and compared their frequency in cases versus controls. Researchers from Boston University School of Medicine (BUSM) used these same subjects, but added additional AD risk information (smoking status, diabetes status, education level) to their statistical modeling to increase the power of the study. By doing so they were able to identify two new genes (COBL and SLC10A2) associated with risk of AD in African Americans.

“There are currently no medications for AD that slow or stop the progression of the disease. Genes that increase risk for AD are potential targets for new disease-modifying AD drug therapies. Our study identifies two potentially “drugable” targets,” explains corresponding author Jesse Mez, MD, MS, assistant professor of neurology at BUSM and associate director of the Boston University Alzheimer’s Disease & CTE Center Clinical Core.

According to the researchers the methodology they employed for this study allowed them to make an important discovery without investing more money in genotyping or more effort to recruit volunteers. They believe the a similar methodology could be used for many other diseases to make new genetic discoveries without new large investments.
“Despite the fact that Alzheimer’s disease is more common in African Americans than Caucasians, we understand less about the genes that influence risk of Alzheimer’s in African Americans. Our hope is that this study begins to eliminate that disparity and that ultimately these newly identified genes become targets for Alzheimer’s disease drug development,” added Mez.
ABOUT THIS GENETICS RESEARCH ARTICLE
Source: Gina DiGravio – Boston University Medical Center 
Image Source: NeuroscienceNews.com image is in the public domain.
Original Research: Abstract for “Two novel loci, COBL and SLC10A2, for Alzheimer’s disease in African Americans” by Jesse Mez, Jaeyoon Chung, Gyungah Jun, Joshua Kriegel, Alexandra P. Bourlas, Richard Sherva, Mark W. Logue, Lisa L. Barnes, David A. Bennett, Joseph D. Buxbaum, Goldie S. Byrd, Paul K. Crane, Nilüfer Ertekin-Taner, Denis Evans, M. Daniele Fallin, Tatiana Foroud, Alison Goate, Neill R. Graff-Radford, Kathleen S. Hall, M. Ilyas Kamboh, Walter A. Kukull, Eric B. Larson, Jennifer J. Manly, Alzheimer Disease Genetics Consortium, Jonathan L. Haines, Richard Mayeux, Margaret A. Pericak-Vance, Gerard D. Schellenberg, Kathryn L. Lunetta, and Lindsay A. Farrer in Alzheimer’s & Dementia. Published online October 19 2016 doi:10.1016/j.jalz.2016.09.002


Abstract

Two novel loci, COBL and SLC10A2, for Alzheimer’s disease in African Americans
Introduction
African Americans’ (AAs) late-onset Alzheimer’s disease (LOAD) genetic risk profile is incompletely understood. Including clinical covariates in genetic analyses using informed conditioning might improve study power.

Methods
We conducted a genome-wide association study (GWAS) in AAs employing informed conditioning in 1825 LOAD cases and 3784 cognitively normal controls. We derived a posterior liability conditioned on age, sex, diabetes status, current smoking status, educational attainment, and affection status, with parameters informed by external prevalence information. We assessed association between the posterior liability and a genome-wide set of single-nucleotide polymorphisms (SNPs), controlling for APOE and ABCA7, identified previously in a LOAD GWAS of AAs.

Results
Two SNPs at novel loci, rs112404845 (P = 3.8 × 10−8), upstream of COBL, and rs16961023 (P = 4.6 × 10−8), downstream of SLC10A2, obtained genome-wide significant evidence of association with the posterior liability.

Discussion
An informed conditioning approach can detect LOAD genetic associations in AAs not identified by traditional GWAS.

“Two novel loci, COBL and SLC10A2, for Alzheimer’s disease in African Americans” by Jesse Mez, Jaeyoon Chung, Gyungah Jun, Joshua Kriegel, Alexandra P. Bourlas, Richard Sherva, Mark W. Logue, Lisa L. Barnes, David A. Bennett, Joseph D. Buxbaum, Goldie S. Byrd, Paul K. Crane, Nilüfer Ertekin-Taner, Denis Evans, M. Daniele Fallin, Tatiana Foroud, Alison Goate, Neill R. Graff-Radford, Kathleen S. Hall, M. Ilyas Kamboh, Walter A. Kukull, Eric B. Larson, Jennifer J. Manly, Alzheimer Disease Genetics Consortium, Jonathan L. Haines, Richard Mayeux, Margaret A. Pericak-Vance, Gerard D. Schellenberg, Kathryn L. Lunetta, and Lindsay A. Farrer in Alzheimer’s & Dementia. Published online October 19 2016 doi:10.1016/j.jalz.2016.09.002

http://neurosciencenews.com/genetics-african-american-alzheimers-5346/

No comments:

Post a Comment